The effectiveness of ICIs in NSCLC is well documented, with several clinical trials demonstrating significant improvements in overall survival (OS) and progression-free survival (PFS) rates, with superior OS in patients with high PD-L1 expression (≥50%) [5]. Here, CD274 is linked to non-small cell lung carcinoma.